From: The economic impact of chronic fatigue syndrome in Georgia: direct and indirect costs
All effects estimated relative to not-fatigued (NF) population, (Standard Errors in Parentheses) | ||||||
---|---|---|---|---|---|---|
 | Linear Ordinary Least Squares (OLS) for Untransformed Cost (y) | |||||
 | Total Expenditures ($2005) | Inpatient Hospital Expenditures ($2005) | Ambulatory Provider Visits ($2005) | Rx Medications ($2005) | OTC Medications ($2005) | Other Health Costs ($2005) |
Incremental Expenditures attributed to CFS | 3084.95*** (799.09) | 476.11 (437.06) | 1590.70*** (598.98) | 919.18*** (293.37) | 111.99*** (36.98) | -13.03 (12.43) |
Incremental Expenditures Attributed to ISF | 1119.75** (476.46) | 262.89 (254.04) | 364.41 (272.99) | 448.54*** (142.68) | 31.81 (26.80) | 12.09 (11.35) |
AIC | 8303.74 | 7815.93 | 7654.30 | 6969.76 | 5196.03 | 6361.90 |
BIC | 8306.15 | 7818.34 | 7656.70 | 6972.17 | 5198.44 | 6364.30 |
 | Generalized Linear Model for Untransformed Cost ((y+1)) a | |||||
Incremental Expenditures attributed to CFS | 3285.54*** (1026.50) | 519.95 (582.17) | 1343.25** (587.55) | 1241.13* (694.19) | 204.01* (111.16) | -1.83 (1.28) |
Incremental Expenditures Attributed to ISF | 1058.27*** (352.68) | 71.61 (122.50) | 384.73 (250.49) | 317.41** (131.90) | 46.83 (30.66) | 0.82 (1.37) |
AIC | 17.33 | 11.12 | 16.62 | 12.54 | 10.37 | 2.68 |
BIC | -2045.41 | 1178.77 | -1739.82 | -205.99 | -925.17 | -2767.13 |
 | Two-Part Model (TPM) for Untransformed Cost (y)b | |||||
Incremental Expenditures Attributed to CFS | 3618.21*** (1285.90) | 602.70 (907.17) | 1622.69*** (553.52) | 1192.25*** (391.32) | 189.13*** (54.14) | -16.30 (21.12) |
Incremental Expenditures Attributed to ISF | 1151.63 (751.45) | 128.18 (577.98) | 416.12 (322.03) | 473.56*** (180.19) | 63.30** (25.14) | 30.11 (37.49) |
AIC | 292.26 | 150.16 | 463.65 | 548.09 | 564.80 | 86.65 |
BIC | -2113.67 | 1359.96 | -1250.64 | 371.70 | -328.59 | -1313.92 |